| AZD5423 Multiple Ascending Dose Study (NCT01037504) | AstraZeneca | 2010-01-01 |
| Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes (NCT01029886) | AstraZeneca | 2010-01-01 |
| Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients (NCT01055652) | AstraZeneca | 2010-01-01 |
| Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler® (NCT01048333) | AstraZeneca | 2010-01-01 |
| Impact of Morning Symptoms in Clinical Control of Chronic Obstructive Pulmonary Disease (COPD) (NCT01266395) | AstraZeneca | 2010-01-01 |
| Evaluation of Target Organs Damage in Hypertensive Patients (NCT01055353) | AstraZeneca | 2010-01-01 |
| Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients (NCT01069289) | AstraZeneca | 2010-01-01 |
| Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments (NCT01086293) | AstraZeneca | 2010-01-01 |
| A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets (NCT01055691) | AstraZeneca | 2010-01-01 |
| Symbicort Turbuhaler 30/60 Clinical Experience Investigation (NCT01232348) | AstraZeneca | 2010-01-01 |
| A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan (NCT01070784) | AstraZeneca | 2010-01-01 |
| Connection Between General Practitioner's (GP's) Estimation of Cardiovascular Risk and Theoretical Calculation in France (NCT01039402) | AstraZeneca | 2009-12-01 |
| A Healthy Volunteer Study to Evaluate Reversibility of Induced Impairment of Cognition (NCT01044342) | AstraZeneca | 2009-12-01 |
| Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis (NCT00812045) | AstraZeneca | 2009-12-01 |
| Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers (NCT01037725) | AstraZeneca | 2009-12-01 |
| Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo (NCT01049360) | AstraZeneca | 2009-12-01 |
| AZD Single Ascending Dose Study In Healthy Japanese Subjects (NCT01028040) | AstraZeneca | 2009-12-01 |
| Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects (NCT01046630) | AstraZeneca | 2009-12-01 |
| Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Track (GIT) Symptoms in Thailand (NCT00999063) | AstraZeneca | 2009-12-01 |
| Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients (NCT01047553) | AstraZeneca | 2009-12-01 |
| A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience (NCT01043185) | AstraZeneca | 2009-12-01 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014 (NCT01026402) | AstraZeneca | 2009-12-01 |
| Observational Study to Estimate the Rates of Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI) With Drug Eluting Stent (DES) Implantation Who Take Statins (NCT01047176) | AstraZeneca | 2009-12-01 |
| The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil (NCT01024660) | AstraZeneca | 2009-12-01 |
| Management of Index Episode in Patients With Bipolar Disorder Treated by Seroquel XR (NCT01029145) | AstraZeneca | 2009-12-01 |
| 4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (NCT01039701) | AstraZeneca | 2009-12-01 |
| Study to Assess Safety, Tolerability and Pharmacokinetics After Single and Multiple Doses of AZD1446 to Japanese Subject (NCT01021189) | AstraZeneca | 2009-12-01 |
| A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease (NCT01016951) | AstraZeneca | 2009-12-01 |
| This is a Study to Determine the Antidepressant Effects of AZD6765 (NCT00986479) | AstraZeneca | 2009-12-01 |
| A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus. (NCT01031836) | AstraZeneca | 2009-11-25 |
| An Epidemiological Study on Antimicrobial Treatment of Nosocomial Infections in Clinical Practice (NCT00864929) | AstraZeneca | 2009-11-01 |
| PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients (NCT01020604) | AstraZeneca | 2009-11-01 |
| Observational Study to Evaluate Bipolar Disorder Symptoms in Patients Presented With Schizophrenia or Depression (NCT01028196) | AstraZeneca | 2009-11-01 |
| Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State (NCT01002807) | AstraZeneca | 2009-11-01 |
| Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR (NCT01192152) | AstraZeneca | 2009-11-01 |
| Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients. (NCT01012375) | AstraZeneca | 2009-11-01 |
| Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN) (NCT01192139) | AstraZeneca | 2009-11-01 |
| AZD9668 Relative Bioavailability (NCT01035411) | AstraZeneca | 2009-11-01 |
| Centralized Pan-South African Survey on the Undertreatment of Hypercholesterolaemia (NCT01027624) | AstraZeneca | 2009-11-01 |
| A Study in Healthy Volunteers to Assess the Tolerability and Blood Levels of a Single Dose of AZD7687 (NCT01046357) | AstraZeneca | 2009-11-01 |
| Study Comparing Esomeprazole and ASA Combined Together as One Capsule Versus These Medications Taken Separately (NCT01015729) | AstraZeneca | 2009-11-01 |
| AZD7268 Safety and Tolerability Study (NCT01020799) | AstraZeneca | 2009-11-01 |
| This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses (NCT01027234) | AstraZeneca | 2009-11-01 |
| Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD) (NCT01019928) | AstraZeneca | 2009-11-01 |
| An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML) (NCT01019161) | AstraZeneca | 2009-11-01 |
| Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia (NCT01025388) | AstraZeneca | 2009-11-01 |
| Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population. Database Analysis of Previous Studies Performed in Spain (NCT00998062) | AstraZeneca | 2009-11-01 |
| Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol (NCT01023516) | AstraZeneca | 2009-11-01 |
| Prevalence of Gastroesophageal Reflux Disease in Primary Care Patients With Upper Gastrointestinal Symptoms (NCT01020890) | AstraZeneca | 2009-11-01 |
| Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent (NCT01025479) | AstraZeneca | 2009-11-01 |
| AZD9668 Relative Bioavailability (NCT01034982) | AstraZeneca | 2009-11-01 |
| This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects (NCT01030224) | AstraZeneca | 2009-11-01 |
| Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35) (NCT01044459) | AstraZeneca | 2009-11-01 |
| The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics (NCT00986531) | AstraZeneca | 2009-11-01 |
| Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States (NCT01031277) | AstraZeneca | 2009-11-01 |
| Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours (NCT00979134) | AstraZeneca | 2009-10-21 |
| Evaluation of Diabetes Care at Austrian GPs (NCT00979394) | AstraZeneca | 2009-10-01 |
| Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand (NCT01130961) | AstraZeneca | 2009-10-01 |
| A Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1446 Administered for 4 Weeks in Elderly Healthy Volunteers (NCT00997308) | AstraZeneca | 2009-10-01 |
| A Descriptive Study to Explore Certain Characteristics of Patients at Risk for Chronic Obstructive Pulmonary Disease (COPD) in a Primary Care Setting (NCT01013922) | AstraZeneca | 2009-10-01 |
| 10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies (NCT00997945) | AstraZeneca | 2009-10-01 |
| Seroquel XR in Schizophrenia Relapse Prevention (NCT00990626) | AstraZeneca | 2009-10-01 |
| Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Volunteers (NCT00977626) | AstraZeneca | 2009-10-01 |
| Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI (NCT01005251) | AstraZeneca | 2009-10-01 |
| Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes (NCT01003184) | AstraZeneca | 2009-10-01 |
| Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients. (NCT01003158) | AstraZeneca | 2009-10-01 |
| Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes (NCT01006590) | AstraZeneca | 2009-10-01 |
| The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen (NCT00999466) | AstraZeneca | 2009-10-01 |
| Study of Artery Conditions of 'At-risk' Asian People Not on Lipid-lowering Drugs (NCT00970918) | AstraZeneca | 2009-10-01 |
| Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin (NCT01006603) | AstraZeneca | 2009-10-01 |
| Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes (NCT00976495) | AstraZeneca | 2009-10-01 |
| Metabolic Syndrome Observation on a Regional Basis (NCT00933010) | AstraZeneca | 2009-10-01 |
| AZD8683 Single Ascending Dose Study (NCT00979849) | AstraZeneca | 2009-10-01 |
| Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients (NCT01001494) | AstraZeneca | 2009-10-01 |
| Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients (NCT01020123) | AstraZeneca | 2009-10-01 |
| Dapagliflozin DPPIV Inhibitor add-on Study (NCT00984867) | AstraZeneca | 2009-10-01 |
| A Study Evaluating the Treatment Selection and Outcome When Changing Antipsychotic Treatment in Schizophrenic Patients (NCT00999895) | AstraZeneca | 2009-10-01 |
| Factors Determining Quality of Life Related to Respiratory Status According to Gender of Chronic Obstructive Pulmonary Disease (COPD) Patients (NCT01007734) | AstraZeneca | 2009-10-01 |
| Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea (NCT00995787) | AstraZeneca | 2009-10-01 |
| Open-Label Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetics (PK) Following a Single Oral Dose of AZD1236 in Healthy Male Subjects (NCT01007929) | AstraZeneca | 2009-10-01 |
| Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients (NCT00999882) | AstraZeneca | 2009-10-01 |
| Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain (NCT00976534) | AstraZeneca | 2009-09-01 |
| Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects (NCT00972049) | AstraZeneca | 2009-09-01 |
| Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia (NCT00984529) | AstraZeneca | 2009-09-01 |
| Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia (NCT00954122) | AstraZeneca | 2009-09-01 |
| Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone (NCT00992381) | AstraZeneca | 2009-09-01 |
| Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects (NCT00984477) | AstraZeneca | 2009-09-01 |
| A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes (NCT00960661) | AstraZeneca | 2009-09-01 |
| Lung Deposition Via Different Inhalation Devices (NCT00975754) | AstraZeneca | 2009-09-01 |
| Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients (NCT00989833) | AstraZeneca | 2009-09-01 |
| Study Comparing Esomeprazole and Acetylsalicylic Acid (ASA) Combined Together as One Capsule Versus These Medications Taken Separately (NCT00998075) | AstraZeneca | 2009-09-01 |
| A Study for the Assessment of the Words Used by Patients and Physicians to Express Asthma Symptoms (NCT00986219) | AstraZeneca | 2009-09-01 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043 (NCT00984880) | AstraZeneca | 2009-09-01 |
| Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer (NCT00956280) | AstraZeneca | 2009-09-01 |
| Non-interventional (NI) Study to Observe Efficacy and Usage of Quetiapine in Acute Episodes of Schizophrenia and as Maintenance Therapy Following Standard Clinical Practice in Croatia (NCT00981123) | AstraZeneca | 2009-09-01 |
| Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m (NCT00997230) | AstraZeneca | 2009-09-01 |
| A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies (NCT00981721) | AstraZeneca | 2009-09-01 |
| Epidemiology of Schizophrenia in Bulgaria (NCT00984373) | AstraZeneca | 2009-09-01 |
| Risk of Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments (NCT01377935) | AstraZeneca | 2009-08-01 |
| Nis Register Study Comparing Seroquel and Seroquel Prolong (NCT00965536) | AstraZeneca | 2009-08-01 |